Notch Therapeutics Appoints Cellular Immunotherapy Veteran Chris Bond, Ph.D. as SVP, Preclinical and Translational Sciences
The Pharma Data
JANUARY 24, 2021
a biotechnology company developing renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Chris Bond , Ph.D. Dr. Bond joins Notch from Kite, where he most recently served as Vice President of Cellular Engineering. . VANCOUVER, BC , Jan.
Let's personalize your content